Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.69 |
| ▸ | AKT2 | P31751 | 11/20 | 0.69 |
| ▸ | AKT3 | Q9Y243 | 7/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27226460 | 1.00 | AKT1 (0.69) | AKT1AKT2AKT3 | |
| SCHEMBL30815347 | 0.89 | AKT1 (0.74) | AKT1AKT2AKT3 | |
| SCHEMBL27226764 | 0.89 | AKT1 (0.74) | AKT1AKT2AKT3 | |
| SCHEMBL30815212 | 0.89 | AKT1 (0.69) | AKT1AKT2AKT3 | |
| SCHEMBL27226286 | 0.89 | AKT1 (0.69) | AKT1AKT2AKT3 | |
| SCHEMBL2191487 | 0.89 | AKT1 (0.77) | AKT1AKT2AKT3 | |
| SCHEMBL30815586 | 0.88 | AKT1 (0.68) | AKT1AKT2AKT3 | |
| SCHEMBL27226452 | 0.88 | AKT1 (0.68) | AKT1AKT2AKT3 | |
| SCHEMBL30815612 | 0.88 | AKT1 (0.70) | AKT1AKT2AKT3 | |
| SCHEMBL27226141 | 0.88 | AKT1 (0.70) | AKT1AKT2AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4594318-A1 | AKT1 MODULATORS | Alterome Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250092040-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11999730-B1 | AKT1 modulators | ALTEROME THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240174667-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024073371-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | AKT1 2/4885AKT2 3/4885AKT3 4/4885 |
| US-20250092040-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | AKT1 2/4885AKT2 3/4885AKT3 4/4885 |
| US-11999730-B1 | AKT1 modulators | AKT1S1, AKT1, AKT2 | AKT1 2/4885AKT2 3/4885AKT3 4/4885 |
| US-20240174667-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | AKT1 2/4885AKT2 3/4885AKT3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.